Evidence map›Paper›PMID 41861752›Full record

Trial reportESMO open2026

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

C Gong, Y Zhao, L Wang, J Cao, Z Tao, T Li, M Zhao, H Miao, X Hu, B Wang

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C GongDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Y ZhaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
L WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
J CaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Z TaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
T LiDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
M ZhaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
H MiaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
X HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: xchu2009@hotmail.com.
B WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: wangbiyun0107@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatinum-based regimens play an essential role in triple-negative breast cancer (TNBC) treatment, with the CBCSG006 study establishing the position of gemcitabine plus cisplatin (GP) as a first-line treatment of metastatic TNBC. Our study aims to further improve the efficacy of the first-line platinum-based chemotherapy for metastatic TNBC by optimizing the selection of platinum. PATIENTS AND

methodsA prospective, randomized, controlled phase II clinical trial was conducted to compare the efficacy and safety of the GP regimen with those of the gemcitabine plus carboplatin (GC) regimen as first-line treatment of patients with metastatic TNBC. A total of 150 untreated metastatic TNBC patients were enrolled and randomized 1 : 1 to receive either the GP or GC regimen until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival, objective response rate (ORR), and safety.

resultsAfter a median follow-up of 57.1 months (interquartile range 42.0-85.7 months), the median PFS for the GP and GC regimen was 7.8 months and 7.0 months, respectively (stratified hazard ratio 0.86; 95% confidence interval 0.59-1.25; P = 0.43); median overall survival was 20.3 months and 19.3 months, respectively (stratified hazard ratio of 1.05; 95% confidence interval 0.73-1.52; P = 0.79). The ORR of the GP regimen was higher than that of the GC regimen (49.3% versus 41.3%, P = 0.33). Grade 3-4 non-hematological adverse events (including nausea, vomiting, and hearing impairment) was more common in the GP group. The incidence of grade 3-4 hematological adverse events (including leukemia, thrombocytopenia, neutropenia, and anemia) was slightly higher in the GC group. No treatment-related death was reported in this study.

conclusionsCisplatin was not associated with a survival advantage over carboplatin when combined with gemcitabine as a first-line treatment of patients with metastatic TNBC, though numerically longer PFS and higher ORR were observed. Differences in safety profiles may help guide individualized treatment decisions.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarboplatinCisplatinDeoxycytidineTriple Negative Breast NeoplasmsAdultFemaleGemcitabineHumansMiddle AgedProspective StudiesCarboplatinCisplatinDeoxycytidineGemcitabineplatinum agentsrandomized controlled clinical trialstriple-negative breast cancer

Identifiers

PMID41861752
PMCPMC13010424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.